Project Description

NM-LogoNeurMedix, Inc. is a clinical-stage biopharmaceutical company that engages in developing products for the treatment of neurological and neuro-degenerative disorders. The company’s product candidates have successfully completed 17 pre-clinical, Phase I, Phase I/II, and Phase II clinical studies, and is entering clinical trials for the treatment of patients with severe Parkinson’s disease, migraine, post operative cognitive dysfunction (POCD), and inclusion-body myositis (IBM). Further studies are contemplated for ALS, Huntington’ Diseases, Alzheimer’s disease, and Encephalitis. Nearly $100 million has been invested on developing NE3107. The company’s focus is on diseases with tremendous unmet medical needs in order to expedite FDA approvals and commercialization, minimize capital requirement and optimize shareholder value.

Project Details